Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into thermogenic, brown-like adipose tissue. Raziel’s prime-candidate, RZL-012, is a first-in-class, currently in clinical development to treat obesity and related disorders. Raziel launched its clinical trial in the US at Q4 2015, expectin...
Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug (NCE) that after a single injection into subcutaneous fat, converts white adipose tissue (WAT) into thermogenic, brown-like adipose tissue. Raziel’s prime-candidate, RZL-012, is a first-in-class, currently in clinical development to treat obesity and related disorders. Raziel launched its clinical trial in the US at Q4 2015, expecting final data that include safety and efficacy, by mid of 2016.

List your booth number for exhibitions, ask us